Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
US TresibaⓇ label reflects the distinctly different product
features compared to competitor basal insulins
Duration of action¹
•
Administration
and dosing
Pen device
In-use time
.
TRESIBA
insulin degludec injection
At least 42 hours²
Once daily at any time of day5
Numerically lower dose needed
vs glargine U1008
glargine U100
•
Up to 24 hours³
Once daily at any time of
day, at the same time every
day6
•
glargine U300
•
Up to 36 hours4
Slide 69
Once daily at any time during
the day, at the same time
every day?
Higher dose needed vs
glargine U100⁹
600 units/pen10
•
300 units/pen
•
450 units/pen
160 units max per injection 10
No push button extension
•
80 units max per injection
•
80 units max per injection
•
Push button extension
•
Push button extension
56 days at room temperature
28 days at room temperature
•
42 days at room temperature
Note: Comparison based on US Package Inserts (PI) for listed products, not based on head to head comparisons.
1 Based on Glucose Infusion Rate (GIR) data from euglycemic clamp studies; 2 Tresiba PI section 12.2; 3 glargine U100 PI section 12.2; 4 glargine U300 PI section 12.2; 5 Tresiba PI Highlights section;
6 glargine U100 PI Highlights section; 7 glargine U300 PI Highlights section; 8 Tresiba PI section 14; 9 glargine U300 PI section 14.1; 10 Tresiba U200 PI
changing
diabetes
novo nordiskView entire presentation